LMP1 and LMP2 may be prognostic factors for outcome of therapy in nasopharyngeal cancers in Indonesia.
Hariwiyanto
Bambang
B
ENT Department Faculty of Medicine, Gadjah Mada University/ Sardjito Hospital, Yogjakarta, Indonesia. bhariwiyanto@yahoo.com
Sastrowiyoto
Sunarto
S
Mubarika
Sofia
S
Salugu
Maesadji
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant; D002648:Child; D003131:Combined Modality Therapy; D020031:Epstein-Barr Virus Infections / Q000378:metabolism* / Q000821:virology; D005260:Female; D004854:Herpesvirus 4, Human / Q000502:physiology*; D006801:Humans; D007124:Immunoenzyme Techniques; D007214:Indonesia; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000378:metabolism* / Q000556:secondary / Q000821:virology; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011379:Prognosis; D011879:Radiotherapy Dosage; D015996:Survival Rate; D014763:Viral Matrix Proteins / Q000378:metabolism*; D055815:Young Adult
C037662:EBV-associated membrane antigen, Epstein-Barr virus; D014763:Viral Matrix Proteins